Efficacy and Safety of Envafolimab Plus Lenvatinib Combined with TACE in Initially Unresectable Hepatocellular Carcinoma: an Open-Label, Single-Arm, Phase II Study
Xueli Bai,Yiwen Chen,Junlei Zhang,Wendi Hu,Xiang Li,Yan Shen,Min Zhang,Jian Wu,Shunliang Gao,Jun Yu,Risheng Que,Yun Zhang,Fuchun Yang,Weiliang Xia,Aibin Zhang,Xiaofeng Tang,Tingbo Liang
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.4108
IF: 45.3
2024-01-01
Journal of Clinical Oncology
Abstract:4108 Background: TACE-based conversion therapies are warranted for over 70% of patients with intermediate-advanced unresectable hepatocellular carcinoma (uHCC). This study aimed to investigate the efficacy and safety of envafolimab plus lenvatinib and TACE as conversion therapy in uHCC. Methods: This is an open-label, prospective, single-arm, phase II study. Eligible patients with uHCC (Barcelona Clinic Liver Cancer Stage B or C) were consecutively enrolled. Patients will receive envafolimab subcutaneously (300 mg, Q3W) and Lenvatinib orally daily (12 mg/day (body weight ≥ 60 kg) or 8 mg/day (<60 kg)) during TACE sessions. TACE will be conducted every 6 weeks on demand according to investigators’ evaluation, mainly based on the proportion of viable tumors. The primary endpoint was the objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version1.1 (RECIST 1.1). Secondary endpoints were disease control rate (DCR) and duration of response (DoR) per RECIST 1.1 and mRECIST, progression-free survival (PFS), overall survival (OS), and safety. Results: Between February 2022 and July 2022, 38 patients were enrolled and included for primary efficacy and safety analysis. As of December 13, 2023, the median follow-up of 16.9 months (95CI, 6.7 to 24.2). The ORR and DCR were 47.4% (95%CI, 31.0% to 64.2%) and 78.9% (95%CI, 62.7% to 90.5%) per RECIST 1.1, respectively (with ORR and DCR of both 78.9% per mRECIST). The median PFS (mPFS) was 8.78 months (95CI, 5.23 to not avaliable (NA)), and the median OS (mOS) was immature with 1-year OS of 88.9%. The median DoR assessed per RECIST 1.1 was 6.7 months (7.7 months per mRECIST). Of 38 patients, 17 patients were assessed as successful conversion with a conversion success rate of 44.7%. Sixteen patients underwent surgery with the R0 resection rate of 100%, the pathological complete response (pCR) rate of 31.3%, and major pathological response (MPR) rate of 56.3%. Of 38 patients, overall incidences of AEs of any grade was 97.4%. Grade ≥3 treatment-related adverse events (TRAEs) were observed in 20 (52.6%) patients, which mainly included increased AST (34.2%), increased ALT (18.4%), and decreased platelet count (15.8%). No treatment-related death occurred. Conclusions: Envafolimab combined with lenvatinib and TACE yielded promising survival outcomes and conversion rate with a manageable safety profile in uHCC, representing a potential and feasible conversion therapy regimen for this population. Clinical trial information: NCT05213221 .